Lamotrigine

Lamotrigine is used to treat bipolar disorder, partial epilepsies, lennox gastaut syndrome and seizures, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Dec 27, 1994, and the first generic was approved Jun 21, 2006. FDA's Orange Book lists 159 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $221 million on Lamotrigine across 4.4 million claims for 680,000 beneficiaries.

Lamotrigine is available as 181 NDCs from 23 manufacturers (164 generic, 17 brand), with NADAC prices from $0.03 to $48.63 per EA — the most expensive product costs about 1,798× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.